Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Social, economic, and health impact of the respiratory syncytial virus: a systematic search

Authors: Javier Díez-Domingo, Eduardo G Pérez-Yarza, José A Melero, Manuel Sánchez-Luna, María Dolores Aguilar, Antonio Javier Blasco, Noelia Alfaro, Pablo Lázaro

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

Bronchiolitis caused by the respiratory syncytial virus (RSV) and its related complications are common in infants born prematurely, with severe congenital heart disease, or bronchopulmonary dysplasia, as well as in immunosuppressed infants. There is a rich literature on the different aspects of RSV infection with a focus, for the most part, on specific risk populations. However, there is a need for a systematic global analysis of the impact of RSV infection in terms of use of resources and health impact on both children and adults. With this aim, we performed a systematic search of scientific evidence on the social, economic, and health impact of RSV infection.

Methods

A systematic search of the following databases was performed: MEDLINE, EMBASE, Spanish Medical Index, MEDES-MEDicina in Spanish, Cochrane Plus Library, and Google without time limits. We selected 421 abstracts based on the 6,598 articles identified. From these abstracts, 4 RSV experts selected the most relevant articles. They selected 65 articles. After reading the full articles, 23 of their references were also selected. Finally, one more article found through a literature information alert system was included.

Results

The information collected was summarized and organized into the following topics: 1. Impact on health (infections and respiratory complications, mid- to long-term lung function decline, recurrent wheezing, asthma, other complications such as otitis and rhino-conjunctivitis, and mortality; 2. Impact on resources (visits to primary care and specialists offices, emergency room visits, hospital admissions, ICU admissions, diagnostic tests, and treatments); 3. Impact on costs (direct and indirect costs); 4. Impact on quality of life; and 5. Strategies to reduce the impact (interventions on social and hygienic factors and prophylactic treatments).

Conclusions

We concluded that 1. The health impact of RSV infection is relevant and goes beyond the acute episode phase; 2. The health impact of RSV infection on children is much better documented than the impact on adults; 3. Further research is needed on mid- and long-term impact of RSV infection on the adult population, especially those at high-risk; 4. There is a need for interventions aimed at reducing the impact of RSV infection by targeting health education, information, and prophylaxis in high-risk populations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Diagnosis and management of bronchiolitis. Pediatrics. 2006, 118 (4): 1774-1793. Diagnosis and management of bronchiolitis. Pediatrics. 2006, 118 (4): 1774-1793.
2.
go back to reference Evidence based clinical practice guideline for medical management of bronchiolitis in infants less than 1 year of age presenting with a first time episode. 2006, Children's Hospital Medical Center, Cincinnati (OH) Evidence based clinical practice guideline for medical management of bronchiolitis in infants less than 1 year of age presenting with a first time episode. 2006, Children's Hospital Medical Center, Cincinnati (OH)
4.
go back to reference Bronchiolitis in children: A national clinical guideline. 2006, SIGN, UK Bronchiolitis in children: A national clinical guideline. 2006, SIGN, UK
5.
go back to reference Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ: Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics. 2007, 120 (4): e1076-e1081.PubMed Bloemers BL, van Furth AM, Weijerman ME, Gemke RJ, Broers CJ, van den Ende K, Kimpen JL, Strengers JL, Bont LJ: Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics. 2007, 120 (4): e1076-e1081.PubMed
6.
go back to reference Flight WG, Mutton KJ, Isalska B, Bright-Thomas RJ, Jones AM: A comparison of three different specimen types for the diagnosis of viral respiratory infections in adults with cystic fibrosis. Thorax. 2011, 66: A23-A24. Flight WG, Mutton KJ, Isalska B, Bright-Thomas RJ, Jones AM: A comparison of three different specimen types for the diagnosis of viral respiratory infections in adults with cystic fibrosis. Thorax. 2011, 66: A23-A24.
7.
go back to reference Nadal D, Wunderli W, Meurmann O, Briner J, Hirsiq J: Isolation of respiratory syncytial virus from liver tissue and extrahepatic biliary atresia material. Scand J Infect Dis. 1990, 22 (1): 91-93.PubMed Nadal D, Wunderli W, Meurmann O, Briner J, Hirsiq J: Isolation of respiratory syncytial virus from liver tissue and extrahepatic biliary atresia material. Scand J Infect Dis. 1990, 22 (1): 91-93.PubMed
8.
go back to reference Billings JL, Hertz MI, Savik K, Wendt CH: Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002, 21 (5): 559-566.PubMed Billings JL, Hertz MI, Savik K, Wendt CH: Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002, 21 (5): 559-566.PubMed
9.
go back to reference Agius G, Dindinaud G, Biggar RJ, Peyre R, Vaillant V, Ranger S, Poupet JY, Cisse MF, Castets M: An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J Med Virol. 1990, 30 (2): 117-127.PubMed Agius G, Dindinaud G, Biggar RJ, Peyre R, Vaillant V, Ranger S, Poupet JY, Cisse MF, Castets M: An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J Med Virol. 1990, 30 (2): 117-127.PubMed
10.
go back to reference Falsey AR, Cunningham CK, Barker WH, Kouides RW, Yuen JB, Menegus M, Weiner LB, Bonville CA, Betts RF: Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis. 1995, 172 (2): 389-394.PubMed Falsey AR, Cunningham CK, Barker WH, Kouides RW, Yuen JB, Menegus M, Weiner LB, Bonville CA, Betts RF: Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis. 1995, 172 (2): 389-394.PubMed
11.
go back to reference Falsey AR, Treanor JJ, Betts RF, Walsh EE: Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc. 1992, 40 (2): 115-119.PubMed Falsey AR, Treanor JJ, Betts RF, Walsh EE: Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc. 1992, 40 (2): 115-119.PubMed
12.
go back to reference Fransén H, Sterner G, Forsgren M, Heigl Z, Wolontis S, Svedmyr A, Tunevall G: Acute lower respiratory illness in elderly patients with respiratory syncytial virus infection. Acta Med Scand. 1967, 182 (3): 323-330.PubMed Fransén H, Sterner G, Forsgren M, Heigl Z, Wolontis S, Svedmyr A, Tunevall G: Acute lower respiratory illness in elderly patients with respiratory syncytial virus infection. Acta Med Scand. 1967, 182 (3): 323-330.PubMed
13.
go back to reference Fleming DM, Cross KW: Respiratory syncytial virus or influenza?. Lancet. 1993, 342 (8886-8887): 1507-1510.PubMed Fleming DM, Cross KW: Respiratory syncytial virus or influenza?. Lancet. 1993, 342 (8886-8887): 1507-1510.PubMed
14.
go back to reference Nicholson KG: Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect. 1996, 116 (1): 51-63.PubMedPubMedCentral Nicholson KG: Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect. 1996, 116 (1): 51-63.PubMedPubMedCentral
15.
go back to reference Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH: Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988, 109 (3): 203-208.PubMed Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, Balfour HH: Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988, 109 (3): 203-208.PubMed
16.
go back to reference Walsh EE, Falsey AR, Hennessey PA: Respiratory syncytial virus and other infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med. 1999, 160 (3): 791-795.PubMed Walsh EE, Falsey AR, Hennessey PA: Respiratory syncytial virus and other infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med. 1999, 160 (3): 791-795.PubMed
17.
18.
go back to reference Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010, 375 (9725): 1545-1555.PubMedPubMedCentral Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010, 375 (9725): 1545-1555.PubMedPubMedCentral
19.
go back to reference Prescott WA, Doloresco F, Brown J, Paladino JA: Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. PharmacoEconomics. 2010, 28 (4): 279-293.PubMed Prescott WA, Doloresco F, Brown J, Paladino JA: Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. PharmacoEconomics. 2010, 28 (4): 279-293.PubMed
20.
go back to reference Broughton S, Roberts A, Fox G, Pollina E, Zuckerman M, Chaudhry S, Greenough A: Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax. 2005, 60 (12): 1039-1044.PubMedPubMedCentral Broughton S, Roberts A, Fox G, Pollina E, Zuckerman M, Chaudhry S, Greenough A: Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants. Thorax. 2005, 60 (12): 1039-1044.PubMedPubMedCentral
21.
go back to reference Medrano LC, García-Guereta L: Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J. 2010, 29 (12): 1077-1082. Medrano LC, García-Guereta L: Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study. Pediatr Infect Dis J. 2010, 29 (12): 1077-1082.
22.
go back to reference Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE: Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005, 352 (17): 1749-1759.PubMed Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE: Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005, 352 (17): 1749-1759.PubMed
23.
go back to reference Milstone AM, Perl TM, Valsamakis A: Epidemiology of respiratory viruses in children admitted to an infant/toddler unit. Am J Infect Control. 2012, 40 (5): 462-464.PubMed Milstone AM, Perl TM, Valsamakis A: Epidemiology of respiratory viruses in children admitted to an infant/toddler unit. Am J Infect Control. 2012, 40 (5): 462-464.PubMed
24.
go back to reference Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK: Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012, 206 (1): 56-62.PubMedPubMedCentral Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK: Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012, 206 (1): 56-62.PubMedPubMedCentral
25.
go back to reference Cilla G, Onate E, Pérez-Yarza EG, Montes M, Vicente D, Pérez-Trallero E: Viruses in community-acquired pneumonia in children aged less than 3 years old: High rate of viral coinfection. J Med Virol. 2008, 80 (10): 1843-1849.PubMed Cilla G, Onate E, Pérez-Yarza EG, Montes M, Vicente D, Pérez-Trallero E: Viruses in community-acquired pneumonia in children aged less than 3 years old: High rate of viral coinfection. J Med Virol. 2008, 80 (10): 1843-1849.PubMed
26.
go back to reference García-García ML, Calvo C, Pozo F, Villadangos PA, Pérez-Brena P, Casas I: Spectrum of respiratory viruses in children with community-acquired pneumonia. Pediatr Infect Dis J. 2012, 31 (8): 808-813.PubMed García-García ML, Calvo C, Pozo F, Villadangos PA, Pérez-Brena P, Casas I: Spectrum of respiratory viruses in children with community-acquired pneumonia. Pediatr Infect Dis J. 2012, 31 (8): 808-813.PubMed
27.
go back to reference Johansson N, Kalin M, Hedlund J: Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis. 2011, 43 (8): 609-615.PubMed Johansson N, Kalin M, Hedlund J: Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Scand J Infect Dis. 2011, 43 (8): 609-615.PubMed
28.
go back to reference Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL: The microbiology of asthma. Nat Rev Microbiol. 2012, 10 (7): 459-471.PubMed Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL: The microbiology of asthma. Nat Rev Microbiol. 2012, 10 (7): 459-471.PubMed
29.
go back to reference Calvo C, Pozo F, García-García ML, Sánchez M, López-Valero M, Pérez-Brena P, Casas I: Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010, 99 (6): 883-887.PubMed Calvo C, Pozo F, García-García ML, Sánchez M, López-Valero M, Pérez-Brena P, Casas I: Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010, 99 (6): 883-887.PubMed
30.
go back to reference de González DJ, Ochoa SC: Estudio de variabilidad en el abordaje de la bronquiolitis aguda en España en relación con la edad de los pacientes. An Pediatr (Barc ). 2010, 72 (1): 4-18. de González DJ, Ochoa SC: Estudio de variabilidad en el abordaje de la bronquiolitis aguda en España en relación con la edad de los pacientes. An Pediatr (Barc ). 2010, 72 (1): 4-18.
31.
go back to reference Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, Espinola JA, Camargo CA: Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 2012, 166 (8): 700-706.PubMedPubMedCentral Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, Espinola JA, Camargo CA: Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 2012, 166 (8): 700-706.PubMedPubMedCentral
32.
go back to reference Bamberger E, Srugo I, Abu Raya B, Segal E, Chaim B, Kassis I, Kugelman A, Miron D: What is the clinical relevance of respiratory syncytial virus bronchiolitis?: findings from a multi-center, prospective study. Eur J Clin Microbiol Infect Dis. 2012, 31 (12): 3323-3330.PubMed Bamberger E, Srugo I, Abu Raya B, Segal E, Chaim B, Kassis I, Kugelman A, Miron D: What is the clinical relevance of respiratory syncytial virus bronchiolitis?: findings from a multi-center, prospective study. Eur J Clin Microbiol Infect Dis. 2012, 31 (12): 3323-3330.PubMed
33.
go back to reference Ralston S, Hill V: Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr. 2009, 155 (5): 728-733.PubMed Ralston S, Hill V: Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr. 2009, 155 (5): 728-733.PubMed
34.
go back to reference Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A: RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012, 171 (7): 1055-1061.PubMed Shefali-Patel D, Paris MA, Watson F, Peacock JL, Campbell M, Greenough A: RSV hospitalisation and healthcare utilisation in moderately prematurely born infants. Eur J Pediatr. 2012, 171 (7): 1055-1061.PubMed
35.
go back to reference McManus TE, Marley AM, Baxter N, Christie SN, O'Neill HJ, Elborn JS, Coyle PV, Kidney JC: Respiratory viral infection in exacerbations of COPD. Respir Med. 2008, 102 (11): 1575-1580.PubMed McManus TE, Marley AM, Baxter N, Christie SN, O'Neill HJ, Elborn JS, Coyle PV, Kidney JC: Respiratory viral infection in exacerbations of COPD. Respir Med. 2008, 102 (11): 1575-1580.PubMed
36.
go back to reference Beckham JD, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB, Atmar RL: Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005, 50 (4): 322-330.PubMed Beckham JD, Cadena A, Lin J, Piedra PA, Glezen WP, Greenberg SB, Atmar RL: Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect. 2005, 50 (4): 322-330.PubMed
37.
go back to reference Camargo CA, Ginde AA, Clark S, Cartwright CP, Falsey AR, Niewoehner DE: Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med. 2008, 3 (4): 355-359.PubMed Camargo CA, Ginde AA, Clark S, Cartwright CP, Falsey AR, Niewoehner DE: Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med. 2008, 3 (4): 355-359.PubMed
38.
go back to reference De SG, Lampron N, La Forge J, Rouleau I, Bourbeau J, Weiss K, Barret B, Boivin G: Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol. 2009, 46 (2): 129-133. De SG, Lampron N, La Forge J, Rouleau I, Bourbeau J, Weiss K, Barret B, Boivin G: Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations. J Clin Virol. 2009, 46 (2): 129-133.
39.
go back to reference Hutchinson AF, Ghimire AK, Thompson MA, Black JF, Brand CA, Lowe AJ, Smallwood DM, Vlahos R, Bozinovski S, Brown GV, Anderson GP, Irving LB: A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med. 2007, 101 (12): 2472-2481.PubMed Hutchinson AF, Ghimire AK, Thompson MA, Black JF, Brand CA, Lowe AJ, Smallwood DM, Vlahos R, Bozinovski S, Brown GV, Anderson GP, Irving LB: A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. Respir Med. 2007, 101 (12): 2472-2481.PubMed
40.
go back to reference Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM: Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010, 15 (3): 536-542.PubMed Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B, Pandey RM: Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology. 2010, 15 (3): 536-542.PubMed
41.
go back to reference Pérez-Yarza EG, Moreno A, Lázaro P, Mejías A, Ramilo O: The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J. 2007, 26 (8): 733-739.PubMed Pérez-Yarza EG, Moreno A, Lázaro P, Mejías A, Ramilo O: The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J. 2007, 26 (8): 733-739.PubMed
42.
go back to reference Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M: Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis. 2008, 27 (10): 891-899.PubMed Carbonell-Estrany X, Bont L, Doering G, Gouyon JB, Lanari M: Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age. Eur J Clin Microbiol Infect Dis. 2008, 27 (10): 891-899.PubMed
43.
go back to reference Busse WW, Lemanske J, Gern JE: Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010, 376 (9743): 826-834.PubMedPubMedCentral Busse WW, Lemanske J, Gern JE: Role of viral respiratory infections in asthma and asthma exacerbations. Lancet. 2010, 376 (9743): 826-834.PubMedPubMedCentral
44.
go back to reference Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, Schechtman KB, Strunk RC, Castro M: Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012, 130 (1): 91-100.PubMedPubMedCentral Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, Schechtman KB, Strunk RC, Castro M: Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012, 130 (1): 91-100.PubMedPubMedCentral
45.
go back to reference Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM: Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010, 65 (12): 1045-1052.PubMed Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM: Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010, 65 (12): 1045-1052.PubMed
46.
go back to reference Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC: Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011, 12 (5): 580-588.PubMed Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC: Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011, 12 (5): 580-588.PubMed
47.
go back to reference Figueras J, Carbonell X, Quero J, Fernández B, Guzmán J, Echániz I, Doménech E: FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008, 27 (9): 788-793. Figueras J, Carbonell X, Quero J, Fernández B, Guzmán J, Echániz I, Doménech E: FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008, 27 (9): 788-793.
48.
go back to reference Carbonell-Estrany X, Quero J: Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001, 20 (9): 874-879.PubMed Carbonell-Estrany X, Quero J: Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J. 2001, 20 (9): 874-879.PubMed
49.
go back to reference Thorburn K, Eisenhut M, Riordan A: Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children - A ten year 50. perspective. Minerva Anestesiol. 2012, 78 (7): 782-789.PubMed Thorburn K, Eisenhut M, Riordan A: Mortality and morbidity of nosocomial respiratory syncytial virus (RSV) infection in ventilated children - A ten year 50. perspective. Minerva Anestesiol. 2012, 78 (7): 782-789.PubMed
50.
go back to reference Walsh EE, Falsey AR: Respiratory Syncytial Virus infection in adult populations. Infect Disord Drug Targets. 2012, 12 (2): 98-102.PubMed Walsh EE, Falsey AR: Respiratory Syncytial Virus infection in adult populations. Infect Disord Drug Targets. 2012, 12 (2): 98-102.PubMed
51.
go back to reference Paramore LC, Ciuryla V, Ciesla G, Liu L: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004, 22 (5): 275-284.PubMed Paramore LC, Ciuryla V, Ciesla G, Liu L: Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004, 22 (5): 275-284.PubMed
52.
go back to reference The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998, 102 (3 Pt 1): 531-537. The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998, 102 (3 Pt 1): 531-537.
53.
go back to reference Gomaa MA, Galal O, Mahmoud MS: Risk of acute otitis media in relation to acute bronchiolitis in children. Int J Pediatr Otorhinolaryngol. 2012, 76 (1): 49-51.PubMed Gomaa MA, Galal O, Mahmoud MS: Risk of acute otitis media in relation to acute bronchiolitis in children. Int J Pediatr Otorhinolaryngol. 2012, 76 (1): 49-51.PubMed
54.
go back to reference Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK: Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012, 54 (10): 1427-1436.PubMedPubMedCentral Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK: Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012, 54 (10): 1427-1436.PubMedPubMedCentral
55.
go back to reference Hampp C, Kauf TL, Saidi AS, Winterstein AG: Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011, 165 (6): 498-505.PubMed Hampp C, Kauf TL, Saidi AS, Winterstein AG: Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011, 165 (6): 498-505.PubMed
56.
go back to reference García CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, Mejias A: Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010, 126 (6): e1453-e1460.PubMedPubMedCentral García CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, Mejias A: Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010, 126 (6): e1453-e1460.PubMedPubMedCentral
57.
go back to reference Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB: Cost utility of palivizumab prophylaxis among pre-term infants in the United States: A national policy perspective. J Med Econ. 2012, 15 (5): 987-996.PubMed Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB: Cost utility of palivizumab prophylaxis among pre-term infants in the United States: A national policy perspective. J Med Econ. 2012, 15 (5): 987-996.PubMed
58.
go back to reference Lázaro P, Figueras J, Doménech E, Closa R, Echániz I, Wood MA, Fitch K: Coste-efectividad de palivizumab para prevenir el virus respiratorio sincitial en niños prematuros y niños con enfermedad pulmonar crónica en España. Pharmacoecon Span Res Artic. 2007, 4 (2): 59-70. Lázaro P, Figueras J, Doménech E, Closa R, Echániz I, Wood MA, Fitch K: Coste-efectividad de palivizumab para prevenir el virus respiratorio sincitial en niños prematuros y niños con enfermedad pulmonar crónica en España. Pharmacoecon Span Res Artic. 2007, 4 (2): 59-70.
59.
go back to reference Nuijten MJ, Wittenberg W: Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010, 11 (1): 105-115.PubMed Nuijten MJ, Wittenberg W: Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010, 11 (1): 105-115.PubMed
60.
go back to reference Lázaro P, Figueras J, Doménech E, Echániz I, Closa R, Wood M, Fitch K: La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España. Anales de Pediatría. 2006, 65 (4): 316-324. Lázaro P, Figueras J, Doménech E, Echániz I, Closa R, Wood M, Fitch K: La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España. Anales de Pediatría. 2006, 65 (4): 316-324.
61.
go back to reference Blanken M, Bont L, Rovers M: The cost-effectiveness of palivizumab in the prevention of respiratory syncytial virus bronchiolitis: A systematic review. Curr Respir Med Rev. 2011, 7 (3): 203-212. Blanken M, Bont L, Rovers M: The cost-effectiveness of palivizumab in the prevention of respiratory syncytial virus bronchiolitis: A systematic review. Curr Respir Med Rev. 2011, 7 (3): 203-212.
62.
go back to reference Wang D, Bayliss S, Meads C: Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011, 15 (5): iii-124-PubMedCentral Wang D, Bayliss S, Meads C: Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess. 2011, 15 (5): iii-124-PubMedCentral
63.
go back to reference Raya OL, Marquez CS, Navarro-Caballero JA, Villegas PR: Cost-effectiveness of palivizumab in the prevention of hospital admissions for syncytial respiratory virus in pre-term babies born at 32 to 35 weeks. 2006, Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Sevilla Raya OL, Marquez CS, Navarro-Caballero JA, Villegas PR: Cost-effectiveness of palivizumab in the prevention of hospital admissions for syncytial respiratory virus in pre-term babies born at 32 to 35 weeks. 2006, Agencia de Evaluación de Tecnologías Sanitarias de Andalucía, Sevilla
64.
go back to reference Pons JM, Tebe C, Paladio N, Garcia-Altes A, Danes I, Valls IS: Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection. Acta Paediatr. 2011, 100 (3): 324-329.PubMed Pons JM, Tebe C, Paladio N, Garcia-Altes A, Danes I, Valls IS: Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection. Acta Paediatr. 2011, 100 (3): 324-329.PubMed
65.
go back to reference Smart KA, Lanctot KL, Paes BA: The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ. 2010, 13 (3): 453-463.PubMed Smart KA, Lanctot KL, Paes BA: The cost effectiveness of palivizumab: a systematic review of the evidence. J Med Econ. 2010, 13 (3): 453-463.PubMed
66.
go back to reference Groothuis JR, Fryzek JP, Makari D, Steffey D, Martone WJ: Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008. Clin Epidemiol. 2011, 3 (1): 245-250.PubMedPubMedCentral Groothuis JR, Fryzek JP, Makari D, Steffey D, Martone WJ: Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008. Clin Epidemiol. 2011, 3 (1): 245-250.PubMedPubMedCentral
67.
go back to reference Hennus MP, Bem RA, Bos AP, van Vught AJ: Life-threatening respiratory syncytial virus disease in children. Curr Respir Med Rev. 2011, 7 (3): 187-195. Hennus MP, Bem RA, Bos AP, van Vught AJ: Life-threatening respiratory syncytial virus disease in children. Curr Respir Med Rev. 2011, 7 (3): 187-195.
68.
go back to reference Stensballe LG, Simonsen JB, Thomsen SF, Larsen AM, Lysdal SH, Aaby P, Kyvik KO, Skytthe A, Backer V, Bisgaard H: The causal direction in the association between respiratory syncytial virus hospitalization and asthma. J Allergy Clin Immunol. 2009, 123 (1): 131-137.PubMed Stensballe LG, Simonsen JB, Thomsen SF, Larsen AM, Lysdal SH, Aaby P, Kyvik KO, Skytthe A, Backer V, Bisgaard H: The causal direction in the association between respiratory syncytial virus hospitalization and asthma. J Allergy Clin Immunol. 2009, 123 (1): 131-137.PubMed
69.
go back to reference Simoes EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR: The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010, 126 (2): 256-262.PubMed Simoes EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR: The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010, 126 (2): 256-262.PubMed
70.
go back to reference Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ: Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health. 2010, 13 (1): 77-86.PubMed Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ: Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health. 2010, 13 (1): 77-86.PubMed
71.
go back to reference DiFranza JR, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ: Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatr. 2012, 12: 81-PubMedPubMedCentral DiFranza JR, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ: Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatr. 2012, 12: 81-PubMedPubMedCentral
72.
go back to reference Robinson KA, Odelola OA, Saldanha IJ, McKoy NA: Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2012, 2: CD007743-PubMed Robinson KA, Odelola OA, Saldanha IJ, McKoy NA: Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2012, 2: CD007743-PubMed
73.
go back to reference Eisenhut M: Extrapulmonary manifestations of severe respiratory syncytial virus infection-a systematic review. Crit Care. 2006, 10 (4): R107-PubMedPubMedCentral Eisenhut M: Extrapulmonary manifestations of severe respiratory syncytial virus infection-a systematic review. Crit Care. 2006, 10 (4): R107-PubMedPubMedCentral
74.
go back to reference Hu J, Robinson JL: Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr. 2010, 6 (4): 296-300.PubMed Hu J, Robinson JL: Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr. 2010, 6 (4): 296-300.PubMed
75.
go back to reference Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, Bonini S, Bont L, Bossios A, Bousquet J, Braido F, Brusselle G, Canonica GW, Carlsen KH, Chanez P, Fokkens WJ, Garcia-Garcia M, Gjomarkaj M, Haahtela T, Holgate ST, Johnston SL, Konstantinou G, Kowalski M, Lewandowska-Polak A, Lodrup-Carlsen K, Mäkelä M, Malkusova I, Mullol J, Nieto A, Eller E, et al: Viruses and bacteria in acute asthma exacerbations-a GA(2) LEN-DARE systematic review. Allergy. 2011, 66 (4): 458-468.PubMed Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, Bonini S, Bont L, Bossios A, Bousquet J, Braido F, Brusselle G, Canonica GW, Carlsen KH, Chanez P, Fokkens WJ, Garcia-Garcia M, Gjomarkaj M, Haahtela T, Holgate ST, Johnston SL, Konstantinou G, Kowalski M, Lewandowska-Polak A, Lodrup-Carlsen K, Mäkelä M, Malkusova I, Mullol J, Nieto A, Eller E, et al: Viruses and bacteria in acute asthma exacerbations-a GA(2) LEN-DARE systematic review. Allergy. 2011, 66 (4): 458-468.PubMed
76.
go back to reference Wang D, Cummins C, Bayliss S, Sandercock J, Burls A: Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008, 12 (36): iii-ix-x, 1-86 Wang D, Cummins C, Bayliss S, Sandercock J, Burls A: Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess. 2008, 12 (36): iii-ix-x, 1-86
77.
go back to reference Carbonell-Estrany X, Simoes EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA: Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010, 125 (1): e35-e51.PubMed Carbonell-Estrany X, Simoes EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA: Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010, 125 (1): e35-e51.PubMed
78.
go back to reference Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP: A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011, 70 (2): 186-191.PubMed Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP: A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res. 2011, 70 (2): 186-191.PubMed
79.
go back to reference Poorisrisak P, Halkjaer LB, Thomsen SF, Stensballe LG, Kyvik KO, Skytthe A, Schioetz PO, Bisgaard H: Causal direction between respiratory syncytial virus bronchiolitis and asthma studied in monozygotic twins. Chest. 2010, 138 (2): 338-344.PubMed Poorisrisak P, Halkjaer LB, Thomsen SF, Stensballe LG, Kyvik KO, Skytthe A, Schioetz PO, Bisgaard H: Causal direction between respiratory syncytial virus bronchiolitis and asthma studied in monozygotic twins. Chest. 2010, 138 (2): 338-344.PubMed
80.
go back to reference Carbonell-Estrany X, Simoes EA, Fullarton JR, Ferdynus C, Gouyon JB: Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med. 2010, 38 (4): 411-417.PubMed Carbonell-Estrany X, Simoes EA, Fullarton JR, Ferdynus C, Gouyon JB: Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med. 2010, 38 (4): 411-417.PubMed
81.
go back to reference Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999, 282 (15): 1440-1446.PubMed Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ: Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999, 282 (15): 1440-1446.PubMed
82.
go back to reference Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ: Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001, 183 (1): 16-22.PubMed Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ: Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001, 183 (1): 16-22.PubMed
83.
go back to reference Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P: The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009, 360 (6): 588-598.PubMedPubMedCentral Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P: The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009, 360 (6): 588-598.PubMedPubMedCentral
84.
go back to reference Willson DF, Landrigan CP, Horn SD, Smout RJ: Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003, 143 (Suppl 5): S142-S149.PubMed Willson DF, Landrigan CP, Horn SD, Smout RJ: Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr. 2003, 143 (Suppl 5): S142-S149.PubMed
85.
go back to reference Korppi M, Piippo-Savolainen E, Korhonen K, Remes S: Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004, 38 (2): 155-160.PubMed Korppi M, Piippo-Savolainen E, Korhonen K, Remes S: Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004, 38 (2): 155-160.PubMed
86.
go back to reference Osundwa VM, Dawod ST, Ehlayel M: Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis in Qatar. Eur J Pediatr. 1993, 152 (12): 1001-1003.PubMed Osundwa VM, Dawod ST, Ehlayel M: Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis in Qatar. Eur J Pediatr. 1993, 152 (12): 1001-1003.PubMed
87.
go back to reference Henderson J, Hilliard TN, Sherriff A, Stalker D, Al SN, Thomas HM: Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005, 16 (5): 386-392.PubMed Henderson J, Hilliard TN, Sherriff A, Stalker D, Al SN, Thomas HM: Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol. 2005, 16 (5): 386-392.PubMed
88.
go back to reference Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, Printz MC, Lee WM, Shult PA, Reisdorf E, Carlson-Dakes KT, Salazar LP, DaSilva DF, Tisler CJ, Gern JE, Lemanske RF: Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008, 178 (7): 667-672.PubMedPubMedCentral Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE, Printz MC, Lee WM, Shult PA, Reisdorf E, Carlson-Dakes KT, Salazar LP, DaSilva DF, Tisler CJ, Gern JE, Lemanske RF: Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008, 178 (7): 667-672.PubMedPubMedCentral
89.
go back to reference Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, Sly PD: Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007, 119 (5): 1105-1110.PubMed Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, Sly PD: Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007, 119 (5): 1105-1110.PubMed
90.
go back to reference Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999, 354 (9178): 541-545.PubMed Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD: Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999, 354 (9178): 541-545.PubMed
91.
go back to reference Fjaerli HO, Farstad T, Rod G, Ufert GK, Gulbrandsen P, Nakstad B: Acute bronchiolitis in infancy as risk factor for wheezing and reduced pulmonary function by seven years in Akershus County. Norway. BMC Pediatr. 2005, 5: 31-PubMed Fjaerli HO, Farstad T, Rod G, Ufert GK, Gulbrandsen P, Nakstad B: Acute bronchiolitis in infancy as risk factor for wheezing and reduced pulmonary function by seven years in Akershus County. Norway. BMC Pediatr. 2005, 5: 31-PubMed
92.
go back to reference Singleton RJ, Redding GJ, Lewis TC, Martinez P, Bulkow L, Morray B, Peters H, Gove J, Jones C, Stamey D, Talkington DF, DeMain J, Bernert JT, Butler JC: Sequelae of severe respiratory syncytial virus infection in infancy and early childhood among Alaska Native children. Pediatrics. 2003, 112 (2): 285-290.PubMed Singleton RJ, Redding GJ, Lewis TC, Martinez P, Bulkow L, Morray B, Peters H, Gove J, Jones C, Stamey D, Talkington DF, DeMain J, Bernert JT, Butler JC: Sequelae of severe respiratory syncytial virus infection in infancy and early childhood among Alaska Native children. Pediatrics. 2003, 112 (2): 285-290.PubMed
93.
go back to reference Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B: Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995, 95 (4): 500-505.PubMed Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B: Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics. 1995, 95 (4): 500-505.PubMed
94.
go back to reference Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000, 161 (5): 1501-1507.PubMed Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000, 161 (5): 1501-1507.PubMed
95.
go back to reference Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005, 171 (2): 137-141.PubMed Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, Kjellman B: Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005, 171 (2): 137-141.PubMed
96.
go back to reference Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000, 137 (6): 865-870.PubMed Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr. 2000, 137 (6): 865-870.PubMed
97.
go back to reference Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D: The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004, 23 (9): 806-814.PubMed Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D: The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004, 23 (9): 806-814.PubMed
98.
go back to reference Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH: Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003, 162 (4): 230-236.PubMed Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH: Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr. 2003, 162 (4): 230-236.PubMed
99.
go back to reference Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, Silvestri M, Pistorio A, Chezzi C: Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007, 166 (12): 1267-1272.PubMedPubMedCentral Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, Silvestri M, Pistorio A, Chezzi C: Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007, 166 (12): 1267-1272.PubMedPubMedCentral
100.
go back to reference Resch B, Pasnocht A, Gusenleitner W, Müller W: Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect. 2005, 50 (5): 397-403.PubMed Resch B, Pasnocht A, Gusenleitner W, Müller W: Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect. 2005, 50 (5): 397-403.PubMed
101.
go back to reference Horn SD, Smout RJ: Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003, 143 (Suppl 5): S133-S141.PubMed Horn SD, Smout RJ: Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003, 143 (Suppl 5): S133-S141.PubMed
102.
go back to reference Hammer J, Numa A, Newth CJ: Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr. 1995, 127 (3): 485-490.PubMed Hammer J, Numa A, Newth CJ: Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr. 1995, 127 (3): 485-490.PubMed
103.
go back to reference Bont L, Steijn M, van Aalderen WM, Kimpen JL: Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J. 2004, 23 (5): 414-417.PubMed Bont L, Steijn M, van Aalderen WM, Kimpen JL: Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J. 2004, 23 (5): 414-417.PubMed
104.
go back to reference Simon A, Khurana K, Wilkesmann A, Müller A, Engelhart S, Exner M, Schildgen O, Eis-Hübinger AM, Groothuis JR, Bode U: Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control. Int J Hyg Environ Health. 2006, 209 (4): 317-324.PubMed Simon A, Khurana K, Wilkesmann A, Müller A, Engelhart S, Exner M, Schildgen O, Eis-Hübinger AM, Groothuis JR, Bode U: Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control. Int J Hyg Environ Health. 2006, 209 (4): 317-324.PubMed
105.
go back to reference Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL: Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007, 151 (1): 34-42. 42.e1PubMed Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, Kimpen JL: Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007, 151 (1): 34-42. 42.e1PubMed
106.
go back to reference Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L: Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013, 368 (19): 1791-1799.PubMed Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L: Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013, 368 (19): 1791-1799.PubMed
108.
go back to reference Grupo de Trabajo de la Guía de Práctica Clínica sobre Bronquiolitis Aguda, Fundació Sant Joan de Déu, coordinador: Guía de Práctica Clínica sobre Bronquiolitis Aguda. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política Social. 2010, Agència d’Avaluació de Tecnologia i Recerca Mèdiques, Barcelona Grupo de Trabajo de la Guía de Práctica Clínica sobre Bronquiolitis Aguda, Fundació Sant Joan de Déu, coordinador: Guía de Práctica Clínica sobre Bronquiolitis Aguda. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política Social. 2010, Agència d’Avaluació de Tecnologia i Recerca Mèdiques, Barcelona
Metadata
Title
Social, economic, and health impact of the respiratory syncytial virus: a systematic search
Authors
Javier Díez-Domingo
Eduardo G Pérez-Yarza
José A Melero
Manuel Sánchez-Luna
María Dolores Aguilar
Antonio Javier Blasco
Noelia Alfaro
Pablo Lázaro
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-014-0544-x

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.